|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on May 13, 2002; DOI 10.1182/blood-2002-03-0777.
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
From the Leukemia Center, Oregon Health and Science
University Cancer Institute, and Department of Molecular and Medical
Genetics, Oregon Health and Science University, Portland; Department of
Haematology, University College Hospital, Galway, Ireland; and Novartis
Pharma, Basel, Switzerland.
In chronic myelogenous leukemia (CML), the development of
chromosomal abnormalities in addition to the Philadelphia chromosome (clonal evolution) is considered by many to be a feature of accelerated phase (AP). Imatinib mesylate (STI571), a selective inhibitor of the
Bcr-Abl tyrosine kinase, has significant activity in AP CML. As clonal
evolution could allow Bcr-Abl independent proliferation, we analyzed
its impact on the outcome of 71 AP patients treated with 600 mg of
imatinib mesylate. Fifteen patients had clonal evolution alone (AP-CE),
32 had AP features but no evidence of clonal evolution (HEM-AP), and 24 had AP features plus clonal evolution (HEM-AP + CE). Of the AP-CE
patients, 73% had a major cytogenetic response, compared with 31% of
the HEM-AP patients (P = .043) and 12.5% of the
HEM-AP + CE patients (P = .007). Complete cytogenetic responses were seen in 60% of AP-CE patients, compared with 31% of HEM-AP patients (P = .19) and 8% of
HEM-AP + CE patients (P < .001). With mean follow-up
of 11.2 months, 35% of all patients failed treatment. The lowest
estimated rate of treatment failure at 1 year, 0%, was seen in AP-CE
patients, compared with rates of 31% for HEM-AP patients and 69% for
HEM-AP + CE patients (P = .0004). After 1 year,
100% of AP-CE patients were still alive, compared with 85% of HEM-AP
patients and 67.5% of HEM-AP + CE patients (P = .01). In conclusion, in patients with clonal evolution as the sole
criterion of disease acceleration, good responses to imatinib are still
possible. Once patients have other signs of acceleration, clonal
evolution predicts lower response rates and a shorter time to
treatment failure.
(Blood. 2002;100:1628-1633) Chronic myelogenous leukemia (CML) is a clonal
hematopoietic stem cell disorder characterized by a specific
chromosomal translocation, t(9;22), resulting in a shortened chromosome
22, commonly referred to as the Philadelphia (Ph)
chromosome.1 The molecular consequence of this
translocation is the generation of a Bcr-Abl fusion
oncogene, resulting in the production of a constitutively
activated Bcr-Abl tyrosine kinase.2 This kinase is capable
of inducing leukemias in mice, implicating Bcr-Abl as the
cause of this disease.3 The tyrosine kinase activity of
the Bcr-Abl protein is essential to its transforming
ability.4
Clinically, CML progresses through 3 distinct phases: chronic phase,
accelerated phase, and blast crisis.5 The chronic phase of
the disease is characterized by massive myeloid expansion with cells
retaining the capacity to differentiate normally. Over time the
capacity for terminal differentiation is lost, resulting in disease
progression. Although Bcr-Abl is thought to be the initial
disease-transforming event in CML, the acquisition of other molecular
and cytogenetic abnormalities is likely to be responsible for disease progression.
The accelerated phase is an intermediate stage in which patients show
signs of disease progression without meeting the criteria for acute
leukemia. This phase is manifested by increasing constitutional symptoms, progressive splenomegaly, and increasing refractoriness to
standard therapy with progressive leucocytosis and/or thrombocytosis. Anemia and thrombocytopenia can also occur. Rising percentages of
blasts and basophils in the bone marrow or peripheral blood are
characteristic. Patients may develop more complex karyotypes, including
trisomy 8, trisomy 19, and isochromosome 17q, with loss of p53 or
additional copies of the Ph chromosome.6,7 In addition, molecular abnormalities such as p53 mutations can arise.8
Until recently, the median survival time of accelerated phase patients
was less than 12 months. For most patients, treatment was
unsatisfactory. Interferon was usually ineffective, and in many cases a
palliative approach was pursued. Allogeneic stem cell marrow
transplantation results in long-term disease-free survival in fewer
than 40% of patients with accelerated phase disease and is unavailable
to most patients owing to lack of a suitable donor or advanced
age.9,10 High-dose chemotherapy followed by autologous
transplantation, using stem cells harvested during the chronic phase,
can establish a second chronic phase, but this is often
short-lived.11 Similarly, intermediate-dose chemotherapy
can restore a temporary chronic phase in some patients but has little
impact on survival.10
Within the past 3 years, a promising new therapy has become available
for the treatment of accelerated phase CML with the introduction of the
Bcr-Abl tyrosine kinase inhibitor imatinib mesylate (formerly STI571)
into clinical trials.12 In the pivotal phase 2 study of
accelerated phase patients, the first patients enrolled were treated
with imatinib mesylate at a dose of 400 mg.13 Once safety
data were available from phase I testing, additional patients were
treated at the higher dose of 600 mg. At this increased dose, a higher
incidence of hematologic and cytogenetic responses was seen, as well as
a significant improvement in time to progression and overall survival.
Overall, 74% of accelerated phase patients treated with imatinib
mesylate at a dose of 600 mg achieved a sustained hematologic response,
which was complete in 41% of cases. Thirty percent of these patients
achieved a major cytogenetic response, 21% of which were complete
responses. Estimated 12-month progression-free and overall survival in
patients receiving 600 mg are 68% and 80%,
respectively.13
Whether the acquisition of additional cytogenetic abnormalities
heralds a transformation to blast crisis and should be considered an
accelerated phase feature has been controversial. A study at MD
Anderson Cancer Center concluded that the prognostic significance of
clonal evolution in CML is not uniform and is related to the specific
abnormality (in particular, chromosome 17 abnormalities carry a worse
prognosis), time to its development, its predominance in metaphases,
and the presence of other accelerated features.14 Clonal
evolution in the absence of other accelerated phase features has not
adversely affected outcome following allogeneic stem cell transplantation.15 Similarly, a previous study using
interferon and low-dose ara-C to treat accelerated phase patients
demonstrated superior survival for patients in whom clonal evolution
was the only criterion for disease acceleration (3-year survival rate 67% vs 22%; P < .01).16 Nevertheless,
the World Health Organization classification of hematopoietic neoplasms
does recognize clonal evolution as a criterion of accelerated
phase.17 Although the initial, pivotal phase 2 study of
imatinib mesylate in accelerated phase patients did not include clonal
evolution as an accelerated phase criterion, a subsequent expanded
access study did allow patients with clonal evolution to be entered
into an accelerated phase study. Because imatinib mesylate targets
Bcr-Abl tyrosine kinase alone and because additional oncogenic
abnormalities could potentially allow Bcr-Abl-independent
proliferation, we analyzed the impact of clonal evolution on the
therapeutic response to imatinib mesylate in the treatment of
accelerated phase CML patients.
Patient samples and clinical and laboratory data
Chromosome preparations
FISH Cells fixed in 3:1 methanol acetic acid were dropped onto slides and treated to optimize spreading, similar to routine metaphase chromosome preparation. Slides were baked at 95°C for 5 to 6 minutes, incubated in 2 × SSC at 37°C for 30 minutes, dehydrated through an alcohol series (70%, 80%, and 95% for 2 minutes each), and dried. Direct-labeled probes for the t(9;22) translocation breakpoints (Ventana [Oncor] double fusion Bcr-Abl D-FISH set, catalog no. P5161-DC; Tucson, AZ) were co-denatured with the target DNA at 72°C for 2 minutes and allowed to renature overnight at 37°C. Slides were then rinsed in 0.5 × SSC at 72°C for 5 minutes and transferred to phosphate-nonadet buffer for 3 minutes. Preparations were counterstained with DAPI (4,6 diamidino-2-phenylindole) for visualization of red, green, and yellow probe signals and analyzed through a Zeiss Axiophot (Oberkochen, Germany); images were captured with a CytoVision system (Applied Imaging, Santa Clara, CA). At least 200 interphase cells were scored for signal patterns. FISH results for at least one metaphase cell were analyzed when possible, to aid in interpretation of complex signal patterns. The normal signal pattern for both probe sets is 2 red, 2 green.The common abnormal pattern for the double fusion system (D-FISH) is 1 red, 1 green, and 2 yellow signals (representing both the derivative 9 and the derivative 22). Observation of a single interphase cell with 1 red, 1 green, and 2 yellow signals with the D-FISH kit is considered to be positive for the Ph rearrangement. Variations in the signal pattern may reflect underlying complex karyotypes. Statistical analysis Differences in response rates were analyzed with the Fisher exact test. Kaplan-Meier curves were constructed for time to treatment failure and overall survival and compared by means of the log-rank test. Time to treatment failure was defined as the time from the first dose of the drug to the date of discontinuation owing to resistant disease, disease progression to blast crisis, loss of response, toxicity, or death. Those without treatment failure were censored at the date of last contact. Disease progression was defined as transformation to blast crisis.
Patient characteristics The 71 patients meeting the criteria for accelerated phase CML who were included in this study were divided into 3 groups (Table 2). One group had clonal evolution only (AP-CE, n = 15) (Table 3), a second group had accelerated phase features but no evidence of clonal evolution (HEM-AP, n = 32), and a third group had accelerated phase features plus clonal evolution (HEM-AP + CE, n = 24) (Table 4). Clonal evolution included duplication of the Ph chromosome as well as the acquisition of new chromosomal abnormalities. Of the 15 patients with AP-CE, 3 had duplication of the Ph chromosome and 13 had additional abnormalities. We evaluated the rate of complete and major cytogenetic responses with metaphase analysis; the decline in percentage of Bcr-Abl-positive bone marrow cells, using FISH; and time to treatment failure for the 3 different groups.
Impact of clonal evolution on cytogenetic response Eleven (73%) of 15 AP-CE patients had a major cytogenetic response, compared with 10 (31%) of 32 HEM-AP patients (P = .0113) and 3 (12.5%) of 24 HEM-AP + CE patients (P < .001). Complete cytogenetic responses were seen in 9 (60%) of 15 AP-CE patients, compared with 10 (31%) of 32 HEM-AP patients (P = .109) and 2 (8%) of 24 HEM-AP + CE patients (P < .001). These responses were sustained for the duration of the study in all patients. Notably, one AP-CE patient was not considered a responder, owing to insufficient metaphases. This patient had 3% Bcr-Abl-positive cells by FISH, and 9 of 9 and 11 of 11 metaphases have been Ph negative on successive examinations. Inclusion of this patient as a complete cytogenetic responder increases the major and complete cytogenetic response rates in the AP-CE category to 80% and 67%, respectively. One additional HEM-AP + CE patient achieved low-level positivity for Bcr-Abl (4%) by FISH but never grew any metaphases for cytogenetic analysis.In several cases there appear to be discrepancies between the percentages of metaphase and interphase cells positive for Ph and Bcr-Abl, respectively (eg, cases 3 and 7 in Table 3 and cases 1, 3, 13, and 24 in Table 4). Our experience has been that the results from both tests correlate when the percentage of Bcr-Abl-positive cells by interphase FISH is less than 35%. Above this level, we have occasionally seen discrepant results. Potential reasons for these discrepancies are as follows: metaphase cytogenetics analyzes proliferating cells, while interphase cytogenetics analyzes nondividing cells. In addition, when cells are placed in metaphase culture, they are washed and may be grown for up to 48 hours in culture medium in the absence of imatinib. This may lead to the outgrowth of a highly proliferative fraction of Ph-positive cells. Effect on time to treatment failure and overall survival With a mean follow-up of 11.2 months (range, 1-23 months, SD ±5.3), 35% of all patients failed treatment. The lowest rate of treatment failure, 0% (0 of 15), was seen in AP-CE patients, compared with 28.12% (9 of 32) in HEM-AP patients and 66.7% (16 of 24) in HEM-AP + CE patients (P = .0004). The 1-year estimated rate of treatment failure was 0%, 31%, and 69% for these 3 groups, respectively (Figure 2). The median time to treatment failure in HEM-AP + CE patients was 8 months. Median time to treatment failure has not yet been reached in HEM-AP or AP-CE patients. Compared with HEM-AP + CE patients, both AP-CE and HEM-AP patient groups had a significantly lower rate of treatment failure (P = .0008 and P = .009, respectively). The difference in time to treatment failure between AP-CE and HEM-AP was less significant (P = .03). At the time of analysis, 81.7% of all patients were still alive. AP-CE patients have fared best, with 100% survival, compared with 87.5% of HEM-AP patients and 62.5% of HEM-AP + CE patients (P = .01; Figure 3). Compared with HEM-AP + CE patients, both AP-CE and HEM-AP patient groups had a significant survival advantage (P = .01 and P = .03, respectively), whereas there is currently no significant survival difference between the latter groups (P = .19). The 1-year estimate of survival was 100% in AP-CE patients, 85% in HEM-AP patients, and 67.5% in HEM-AP + CE patients (P = .01).
Cytogenetic clonal evolution may be a marker of disease progression in CML and is thought to reflect the genetic instability of the highly proliferative CML progenitors. Telomere shortening, which has been associated with disease progression, may contribute to this genetic instability.20,21 Regardless of the underlying mechanisms, the net result of additional genetic abnormalities is the potential for a more malignant phenotype and, possibly, less reliance on Bcr-Abl for proliferation and survival. We were interested in determining whether the presence of such abnormalities would affect the outcome of accelerated phase CML patients treated with imatinib mesylate, an agent that specifically targets the Bcr-Abl tyrosine kinase. In this study we observed that patients with clonal evolution as the sole criterion of disease acceleration have excellent responses to imatinib mesylate. However, once patients have other accelerated phase features, the presence of clonal evolution predicts lower response rates and a shorter time to treatment failure. The poorer outcome in this group is perhaps not surprising, and there are now reports of clonal evolution as a mechanism of resistance to imatinib mesylate.22 The outcome of patients with clonal evolution alone compares favorably with the results in chronic phase CML patients treated with imatinib following interferon failure. Major and complete cytogenetic responses of 60% and 41%, respectively, have been reported in this patient population. In this phase 2 study, 400 mg of imatinib mesylate was used daily.23 Although obviously a small group, our AP-CE patients had major and complete responses of 73% and 60%, respectively. Prior to July 2000, patients with clonal evolution alone were entered in chronic phase studies (hence the follow-up of this subgroup in this accelerated phase study is shorter than that of the other 2 groups). We recently analyzed the risk of relapse in 118 chronic patients treated with 400 mg of imatinib mesylate and found that 8 (8%) of 95 patients with the Ph chromosome alone relapsed, compared with 9 (39%) of 23 patients with additional chromosomal abnormalities (P < .001; M.E.O'D., B.J.D., unpublished data, 2002). This suggests that in the absence of accelerated phase features, clonal evolution combined with treatment with imatinib at a dose of 400 mg has an adverse impact on outcome (there was no significant difference in major cytogenetic response rates between these 2 groups). However, when AP-CE patients are treated as accelerated phase patients, with a more aggressive intent, superior results are obtained. Imatinib mesylate was administered at a dose of 600 mg, which has been shown to be superior to 400 mg in the pivotal study in accelerated phase patients.13 In addition, treatment was not withheld because of myelosuppression, unless this was sustained and associated with marrow hypocellularity of less than 10%. In addition, some patients were supported with myeloid growth factors, which allowed continued therapy without dose reductions.24 This suggests that with more aggressive therapy, patients with clonal evolution alone benefit greatly. Clearly, several factors may have contributed to the high response rate seen. In the phase 2 chronic phase study, 5 baseline variables that independently predicted a high rate of major cytogenetic response were determined. These were (1) the absence of blasts in peripheral blood, (2) a hemoglobin (Hb) level higher than 12 g/dL, (3) the presence of fewer than 5% blasts in marrow, (4) a time from diagnosis of CML to start of treatment of less than one year, and (5) a history of cytogenetic relapse during interferon therapy.23 The 15 patients with clonal evolution alone in our study had a median Hb of 12.1, median peripheral blasts of 0%, and median marrow blasts of 1.7%, all favorable prognostic factors. However, the median duration of disease was 38 months, and only 2 of 15 patients had any prior cytogenetic response to interferon (the single most powerful predictor of response). Therefore, it is tempting to speculate that much of the benefit is due either to treatment with a higher dose or to increased dose intensity. Similarly, whether improved responses are seen with more aggressive management of myelosuppression will need to be analyzed. This could include treatment with myeloid growth factors or setting lower platelet thresholds for withholding therapy. Our data also demonstrate that patients with accelerated phase CML and cytogenetic clonal evolution are at high risk of treatment failure when treated with imatinib mesylate alone and should be considered candidates for additional treatments, such as stem cell transplantation or combination regimens as appropriate. Finally, although this is a relatively small group of patients, the high rate of major and complete cytogenetic responses in AP-CE patients suggests that studies comparing 600 mg of imatinib mesylate with the currently recommended dose of 400 mg for chronic phase patients should be considered.
Submitted March 15, 2002; accepted April 22, 2002.
Prepublished online as Blood First Edition Paper, May 13, 2002; DOI 10.1182/blood-2002-03-0777.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Michael E. O'Dwyer, Department of Haematology, University College Hospital, Newcastle Road, Galway, Ireland; e-mail: michael.odwyer{at}whb.ie.
1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132:1497-1501. 2. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining [letter]. Nature. 1973;243:290-293[CrossRef][Medline] [Order article via Infotrieve].
3.
Daley GQ, Van Etten RA, Baltimore D.
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
Science.
1990;247:824-830
4.
Lugo TG, Pendergast AM, Muller AJ, Witte ON.
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
Science.
1990;247:1079-1082 5. O'Dwyer ME, Mauro MJ, Druker BJ. Recent advancements in the treatment of chronic myelogenous leukemia. Annu Rev Med. 2002;53:369-381[CrossRef][Medline] [Order article via Infotrieve]. 6. Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441-1446[CrossRef][Medline] [Order article via Infotrieve]. 7. Bernstein R. Cytogenetics of chronic myelogenous leukemia. Semin Hematol. 1988;25:20-34[Medline] [Order article via Infotrieve].
8.
Ahuja H, Bar-Eli M, Advani SH, Benchimol S, Cline MJ.
Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia.
Proc Natl Acad Sci U S A.
1989;86:6783-6787 9. McGlave P. Bone marrow transplants in chronic myelogenous leukemia: an overview of determinants of survival. Semin Hematol. 1990;27:23-30[Medline] [Order article via Infotrieve]. 10. Griesshammer M, Arnold R, Bangerter M, et al. Chronic myeloid leukemia in accelerated phase: treatment results with conventional chemotherapy and allogeneic bone marrow transplantation in 96 patients. Eur J Haematol. 1998;61:7-13[Medline] [Order article via Infotrieve]. 11. Reiffers J, Trouette R, Marit G, et al. Autologous blood stem cell transplantation for chronic granulocytic leukaemia in transformation: a report of 47 cases. Br J Haematol. 1991;77:339-345[Medline] [Order article via Infotrieve].
12.
Druker BJ, Talpaz M, Resta DJ, et al.
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
N Engl J Med.
2001;344:1031-1037
13.
Talpaz M, Silver RT, Druker BJ, et al.
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Blood.
2002;99:1928-1937 14. Majlis A, Smith TL, Talpaz M, O'Brien S, Rios MB, Kantarjian HM. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol. 1996;14:196-203[Abstract].
15.
Clift RA, Buckner CD, Thomas ED, et al.
Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia.
Blood.
1994;84:4368-4373
16.
Kantarjian HM, Keating MJ, Estey EH, et al.
Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.
J Clin Oncol.
1992;10:772-778 17. World Health Organization Classification of Tumours. Pathology and Genetics of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001. 18. Speck B, Bortin MM, Champlin R, et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet. 1984;1:665-668[Medline] [Order article via Infotrieve]. 19. Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol. 1988;25:49-61[Medline] [Order article via Infotrieve].
20.
Brummendorf TH, Holyoake TL, Rufer N, et al.
Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry.
Blood.
2000;95:1883-1890
21.
Boultwood J, Peniket A, Watkins F, et al.
Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase.
Blood.
2000;96:358-361 22. Kreil S, Mueller M, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy Program and Abstracts of the 43rd Annual Meeting of the American Society of Hematology; Orlando: FL. Abstract; 1823.
23.
Kantarjian H, Sawyers C, Hochhaus A, et al.
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
N Engl J Med.
2002;346:645-652 24. Mauro MJ, Kurilik G, Balleisen B, O'Dwyer, ME, Reese SF, Druker BJ. Myeloid growth factors for neutropenia during imatinib mesylate (STI571) therapy for CML: preliminary evidence of safety and efficacy. In: Program and Abstracts of the 43rd Annual Meeting of the American Society of Hematology; December 7-11, 2001; Orlando, FL. Abstract 584.
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  E. Jabbour, H. M. Kantarjian, L. V. Abruzzo, S. O'Brien, G. Garcia-Manero, S. Verstovsek, J. Shan, M. B. Rios, and J. Cortes Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase Blood, October 15, 2007; 110(8): 2991 - 2995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ray, S. W. Cowan-Jacob, P. W. Manley, J. Mestan, and J. D. Griffin Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study Blood, June 1, 2007; 109(11): 5011 - 5015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Weisberg, L. Catley, R. D. Wright, D. Moreno, L. Banerji, A. Ray, P. W. Manley, J. Mestan, D. Fabbro, J. Jiang, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias Blood, March 1, 2007; 109(5): 2112 - 2120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood, September 15, 2006; 108(6): 1809 - 1820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. von Bubnoff, P. W. Manley, J. Mestan, J. Sanger, C. Peschel, and J. Duyster Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107) Blood, August 15, 2006; 108(4): 1328 - 1333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hughes ABL Kinase Inhibitor Therapy for CML: Baseline Assessments and Response Monitoring Hematology, January 1, 2006; 2006(1): 211 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C. Wolff, D. R. Veach, W. P. Tong, W. G. Bornmann, B. Clarkson, and R. L. Ilaria Jr PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia Blood, May 15, 2005; 105(10): 3995 - 4003. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Secko Targeting hard-to-treat cancers Can. Med. Assoc. J., April 12, 2005; 172(8): 993 - 993. [Full Text] [PDF]
|
|
|
|
|
|
M. W.N. Deininger Management of Early Stage Disease Hematology, January 1, 2005; 2005(1): 174 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Okada, S. Adachi, T. Imai, K.-i. Watanabe, S.-y. Toyokuni, M. Ueno, A. S. Zervos, G. Kroemer, and T. Nakahata A novel mechanism for imatinib mesylate-induced cell death of BCR-ABL-positive human leukemic cells: caspase-independent, necrosis-like programmed cell death mediated by serine protease activity Blood, March 15, 2004; 103(6): 2299 - 2307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Donato, J. Y. Wu, J. Stapley, H. Lin, R. Arlinghaus, B. Aggarwal, S. Shishodin, M. Albitar, K. Hayes, H. Kantarjian, et al. Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia Cancer Res., January 15, 2004; 64(2): 672 - 677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. O'Dwyer, M. J. Mauro, C. Blasdel, M. Farnsworth, G. Kurilik, Y.-C. Hsieh, M. Mori, and B. J. Druker Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate Blood, January 15, 2004; 103(2): 451 - 455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Branford, Z. Rudzki, S. Walsh, I. Parkinson, A. Grigg, J. Szer, K. Taylor, R. Herrmann, J. F. Seymour, C. Arthur, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis Blood, July 1, 2003; 102(1): 276 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Cortes, M. Talpaz, F. Giles, S. O'Brien, M. B. Rios, J. Shan, G. Garcia-Manero, S. Faderl, D. A. Thomas, W. Wierda, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy Blood, May 15, 2003; 101(10): 3794 - 3800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W.N. Deininger, S. G. O'Brien, J. M. Ford, and B. J. Druker Practical Management of Patients With Chronic Myeloid Leukemia Receiving Imatinib J. Clin. Oncol., April 15, 2003; 21(8): 1637 - 1647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Mohamed, P. Pemberton, J. Zonder, and C. A. Schiffer The Effect of Imatinib Mesylate on Patients with Philadelphia Chromosome-positive Chronic Myeloid Leukemia with Secondary Chromosomal Aberrations Clin. Cancer Res., April 1, 2003; 9(4): 1333 - 1337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. McCann, K. Gately, E. Conneally, and M. Lawler Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML Blood, February 1, 2003; 101(3): 1200 - 1200. [Full Text] [PDF]
|
|
|
|
|
|
B. J. Druker, S. G. O'Brien, J. Cortes, and J. Radich Chronic Myelogenous Leukemia Hematology, January 1, 2002; 2002(1): 111 - 135. [Abstract] [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
